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Abstract: Background: GMC1 (2-(1H-benzimidazol-2-ylsulfanyl)-N-[(Z)-(4-methoxyphenyl)
methylideneamino] acetamide) effectively inhibits androgen receptor function by binding directly to
FKBP52. This is a novel mechanism for the treatment of castration resistant prostate cancer (CRPC).
Methods: an LC-MS/MS method was developed and validated to quantify GMC1 in plasma and
urine from pharmacokinetics studies in rats. An ultra-high-performance liquid chromatography
(UHPLC) system equipped with a Waters XTerra MS C18 column was used for chromatographic
separation by gradient elution with 0.1% (v/v) formic acid in water and methanol. A Sciex 4000
QTRAP® mass spectrometer was used for analysis by multiple reaction monitoring (MRM) in
positive mode; the specific ions [M+H]+ m/z 340.995 → m/z 191.000 and [M+H]+ m/z 266.013 →
m/z 234.000 were monitored for GMC1 and internal standard (albendazole), respectively. Results:
GMC1 and albendazole had retention times of 1.68 and 1.66 min, respectively. The calibration
curves for the determination of GMC1 in rat plasma and urine were linear from 1–1000 ng/mL.
The LC-MS/MS method was validated with intra- and inter-day accuracy and precision within the
15% acceptance limit. The extraction recovery values of GMC1 from rat plasma and urine were greater
than 95.0 ± 2.1% and 97.6 ± 4.6%, respectively, with no significant interfering matrix effect. GMC1 is
stable under expected sample handling, storage, preparation and LC-MS/MS analysis conditions.
Conclusions: Pharmacokinetic evaluation of GMC1 revealed that the molecule has a biexponential
disposition in rats, is distributed rapidly and extensively, has a long elimination half-life, and appears
to be eliminated primarily by first order kinetics.
Keywords: GMC1; bioanalytical method; LC-MS/MS; pharmacokinetics; prostate cancer;
drug development
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1. Introduction
Androgen receptor (AR)-regulated genes contribute to the initiation and progression of prostate
cancer (PCa). Signaling via the AR axis is considered to be important in facilitating prostate
carcinogenesis, although the precise mechanisms driving PCa are still being elucidated [1]. Current PCa
therapies antagonize androgen receptors (AR) by competing for its ligand binding site [1–4]. However,
these treatment options become ineffective once androgen-dependence is lost and PCa eventually
moves into a castration resistance state [5–7]. Thus, there is an urgent need for new anti-androgens
with entirely novel mechanisms of action. The 52 kDa FK506 binding protein (FKBP52) is a known
positive regulator of AR as well as glucocorticoid (GR) and progesterone receptors (PR) and β-catenin.
As such, FKBP52 represents a potential therapeutic target in PCa [2,8–13]. A series of small molecules
that selectively inhibit FKBP52, mediated by enhancement of AR signaling by targeting the AR binding
function 3 surface (BF3), have been identified and characterized [2,9,14,15]. More recently, GMC1,
a new chemical entity, was also identified through structure-based in silico screening as a potential
ligand for the FKBP52 peptidyl-prolyl-cis-trans-isomerase (PPIase) pocket [11,13,16]. It has been further
demonstrated that GMC1 effectively inhibits AR and GR activity in a variety of cell lines [16]. The IC50
of GMC1 in MDA-kb2 cell AR reporter assays is 8.83 ± 3.55 µM, and in 52KO MEFs AR reporter
assays is 0.66 ± 0.48 µM. Compared to previously reported FKBP52 inhibitors, GMC1 is predicted
to simultaneously attenuate a variety of targets implicated in prostate cancer. This lead molecule
effectively inhibits receptor activity in the low to mid micro-molar concentrations, AR-dependent
prostate-specific antigen (PSA) secretion from a variety of prostate cancer cells, and 22Rv1 prostate
cancer cell proliferation [2,16].
GMC1 is known by the IUPAC names 2-(1H-benzimidazol-2-ylsulfanyl)-N-[(Z)-(4-methoxyphenyl)
methylideneamino] acetamide or (Z)-2-((1H-benzo[d]imidazol-2-yl) thio)-N0 -(4-methoxybenzylidene)
acetohydrazide. Figure 1 shows its chemical structure. Its molecular formula is C17 H16 N4 O2 S, and it
has an average molecular weight of 340.4 g/mol. GMC1 has an acidic pKa of 10.61 ± 0.10 and basic
pKa of 4.30 ± 0.10 at 25 ◦ C. It has a calculated logP of 3.68 ± 0.57. The development of GMC1 as a
drug is very appealing because it is a first-in-class molecule that directly targets the AR-associated
co-chaperone for the treatment of castration-resistant prostate cancer (CRPC) [13]. For the preclinical
and clinical development of GMC1, a suitable bioanalytical method for its quantification in in vitro
and biological systems is highly essential. The sensitivity and selectivity of the bioanalytical method,
as well as the stability of the analytes under storage conditions must be established in accordance with
regulatory standards.

Figure 1. Chemical structures of (A) GMC1 (2-(1H-benzimidazol-2-ylsulfanyl)-N-[(Z)-(4-methoxyphenyl)
methylideneamino] acetamide) (analyte) and (B) Albendazole (internal standard (IS)). Both compounds
have a benzimidazole backbone. GMC1 has an acidic pKa of 10.61 ± 0.10 and a basic pKa of 4.30 ± 0.10
at 25 ◦ C. It has a calculated log p-value of 3.68 ± 0.57 at room temperature.
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Herein, we report the development and validation of a simple, sensitive, and reproducible liquid
chromatography-tandem mass spectrometry (LC-MS/MS) method for quantification of GMC1 in rat
plasma and urine. We established the specificity, sensitivity and linearity, reproducibility, recovery,
and dilution integrity of the assay in accordance with the United States Food and Drug Administration
(FDA) bioanalytical method validation guidance [17]. Additionally, we assessed the stability of the
analyte in samples under anticipated storage and handling conditions, as well as sample processing
and analytical (LC-MS/MS) procedures. Following an in vivo pharmacokinetic study of GMC1 in adult
male Sprague-Dawley (SD) rats, the fully validated assay method was deployed to determine the
concentration of GMC1 in plasma and urine samples.
2. Results and Discussion
Validated analytical methods for quantification of drugs, their metabolites, and biomarkers are
critical for successful drug discovery undertakings [4]. Herein, we report the development and full
validation of a rapid, sensitive, and reproducible LC-MS/MS method for quantification of GMC1
in plasma and urine samples. The pharmacokinetic disposition of GMC1 in rats was subsequently
evaluated using this analytical method. Our analytical method will therefore be very useful for studies
related to the preclinical and clinical development of GMC1.
2.1. Chromatography and MS Conditions
The mobile phase, chromatographic column, column temperature, and source parameters were
optimized for the signal intensity and peak shape. Symmetrical peak shape and optimal peak intensity
were obtained with a Waters® Xterra MS C18 column (2.1 × 50 mm, 3.5 µm), and 0.1% (v/v) formic acid in
water and 0.1% (v/v) formic acid in methanol as aqueous and organic phases, respectively. Methanol as
the organic phase yielded a better response compared to acetonitrile. Electrospray ionization (ESI)
in positive mode was better suited for this analyte compared to atmospheric chemical ionization
(APCI) and negative mode. Ion source parameters were optimized until the best intensity for the
determination of the analyte was attained. The intensity of the analyte in samples prepared in mobile
or organic phase containing formic acid seemed to diminish over time compared to samples prepared
without any modifiers or additives. Hence standard solutions and protein precipitation solvent were
devoid of formic acid.
The assay run time was 4.5 min, and the mean retention times for GMC1 and albendazole (internal
standard (IS)) were 1.68 and 1.66 min, respectively. Chromatograms obtained from a zero-calibrator
plasma sample, blank rat plasma and urine samples spiked with the lower limit of quantitation (LLOQ)
level (1 ng/mL), and rat plasma sample spiked with IS are depicted in Figure 2. Carryover effect/
needle contamination were prevented by rinsing the needle (in-between each sample injection) with a
strong organic wash solvent containing 60% isopropyl alcohol, 20% acetonitrile, and 20% methanol.
No detectable GMC1 peak was observed in blank samples injected immediately after the upper limit
of quantification (ULOQ) standard.
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Figure 2. LC-MS/MS chromatograms (XIC of multiple reaction monitoring (MRM)) for (A) Double
blank rat plasma sample; (B) Double blank rat urine sample; (C) Rat plasma sample spiked with LLOQ
concentration (1 ng/mL) of GMC1; (D) Rat urine sample spiked with LLOQ concentration (1 ng/mL) of
GMC1; (E) Blank rat plasma sample showing spiked IS.
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2.2. Method Validation
2.2.1. Specificity and Selectivity
The specificity and selectivity of the assay (assessed to preclude interference from components
of biological matrices and cross-reacting molecules) was evaluated by analyzing replicates of blank
samples from different sources. As shown in Figure 2, the blank and zero calibrator samples were
devoid of interfering signal at the observed retention times for both the analyte and internal standard.
The instrument response for IS in blank rat plasma and urine samples was 2.9% and 3.3% of the average
IS response for the standards and quality controls (QCs). In addition to specificity and selectivity,
the observed IS response also indicates that the internal standard is stable when spiked into the
precipitant solvent.
2.2.2. Sensitivity and Linearity
The linear range for calibration curves for the determination of GMC1 in rat plasma and urine
was from 1–1000 ng/mL, respectively, and the co-efficient for linear regression was accepted if greater
than 0.99. The equations for the calibration curves in plasma and urine, respectively, were y = 9.89e−4 x
+ 1.01e−4 and y = 1.54e−3 x + 7.99e−4 . The limit of detection (LOD) was based on a signal-to-noise (S/N)
ratio of 3:1, while the LLOQ was selected based on an S/N ratio of at least 5:1. The measured LLOQ
(1 ng/mL) of GMC1 in rat plasma and urine gave an S/N ratio much greater than five.
2.2.3. Precision, Accuracy and Dilution Integrity
The precision and accuracy were expressed as the coefficient of variation (% CV) and the percentage
relative error (% RE), respectively. The intra-day and inter-day accuracy and precision for all four QC
samples were within the acceptable range: 20% for LLOQ and 15% for low, medium and high QC
(LQC, MQC and HQC). Summarized in Table 1, the data confirm that GMC1 can be accurately and
precisely quantified in rat plasma and urine from 1–1000 ng/mL using our LC-MS/MS method.
Table 1. Accuracy and precision data of LC-MS/MS method for the quantification of GMC1 in various
matrices. Percentage relative error (% RE) and coefficient of variation (CV) ≤ 20% for LLOQ and ≤ 15%
for other QCs are considered acceptable.
Intra-Day (n = 6)

Inter-Day (n = 6)

Biological
Matrix

QC

Nominal
Concentration
(ng/mL)

Accuracy
(RE, %)

Precision
(CV, %)

Accuracy
(RE, %)

Precision
(CV, %)

Plasma

LLOQ
LQC
MQC
HQC

1
2.5
400
800

96
99.9
90.2
89

9.35
10.5
7.1
7.9

93.7
99.6
92.8
91.4

8.4
9.6
2
5.9

Urine

LLOQ
LQC
MQC
HQC

1
2.5
400
800

104.2
101.1
87.4
88.6

9.9
7.6
4.6
7.5

94
93.2
93.5
92.2

11.1
8.4
5.1
5.5

The dilution integrity was assessed by determining the precision and accuracy of samples diluted
several folds with blank plasma. The accuracy and precision of the QC samples were well within 15%
of the nominal concentration and presented CV < 15% (Table 2). The dilution integrity data suggest
that the concentration of GMC1 in samples of greater concentration than the highest calibrator for this
method can be accurately and precisely quantified following dilution with blank plasma and urine at
least up to 50 times.

Pharmaceuticals 2020, 13, 386

6 of 16

Table 2. Dilution integrity. Accuracy and precision demonstrate the effect of dilution on the quantification
of GMC1 using this LC-MS/MS method (n = 6). RE and CV ≤ 15% are considered acceptable.
Biological
Matrix

Dilution
Factor

Accuracy
(RE, %)

Precision
(CV, %)

Plasma

5
10
20
50

104.9
106.9
89.9
98.5

6
3.3
5.6
9.6

Urine

5
12.5
25
50

87.1
97.3
102
88.4

6.2
5.6
3.4
2.6

2.2.4. Extraction Recovery
The ratio of the instrument response (PAR) from a sample spiked with GMC1 before protein
precipitation to the mean instrument response (PAR) from a sample spiked with the analyte after the
protein precipitation procedure, was calculated as the absolute recovery of GMC1 from biological
matrix. Percentage recoveries > 95.0 ± 2.1% and 97.6 ± 4.6% from rat plasma and urine, respectively,
were observed. The data (Table 3) indicate that GMC1 can be efficiently extracted from biological
matrices by simple protein precipitation with methanol.
Table 3. Percentage extraction recovery and matrix factor for the quantification of GMC1 using this
LC-MS/MS method (n = 3; (mean ± SD)). Matrix effect is considered significant if matrix factor is >±15%.
Biological
Matrix

QC

Nominal
Concentration
(ng/mL)

Extraction
Recovery

Matrix
Factor

Plasma

LLOQ
LQC
MQC
HQC

1
2.5
400
800

98.8 ± 9.9
95.0 ± 2.1
98.3 ± 7.4
99.6 ± 4.8

7.9 ± 3.3
7.2 ± 2.9
9.7 ± 2.9
6.7 ± 3.6

Urine

LLOQ
LQC
MQC
HQC

1
2.5
400
800

99.3 ± 4.4
97.6 ± 4.6
99.6 ± 6.8
98.2 ± 5.6

5.1 ± 0.6
2.6 ± 1.1
6.5 ± 3.8
5.1 ± 2.9

2.2.5. Matrix Effect
The effect of biological matrix, expressed as matrix factor, indicates the propensity for analyte
signal suppression or enhancement by co-eluting components of biological matrices during sample
analysis. While a positive matrix factor signifies analyte signal enhancement, a negative matrix factor
suggests analyte signal suppression [18]. The matrix effect is said to be significant if the calculated
matrix factor is greater than ± 15%. The mean matrix factor, summarized in Table 3, suggests that there
was no significant sample matrix effect interposing with the quantification of GMC1 in rat plasma and
urine using our LC-MS/MS method [18].
Analyte signal suppression by co-eluting polyethylene glycol (PEG) 300 in the dosing solution
for pharmacokinetic study was assessed by determining the accuracy and precision of QC samples
containing 1% and 0.1% PEG 300. Accuracies of 107.7% and 108.4%, respectively, were observed for
0.1% PEG QC and 1% PEG 300 QC samples. Precisions for the PEG QC samples were 0.9% and 5.6%,
respectively. The accuracy and precision were within 15% of the nominal concentration and presented
CV < 15%, suggesting that analyte signal interference was not suppressed by PEG 300.
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2.2.6. Analyte Stability
The recovery of GMC1 from QC samples prepared and stored on the bench-top or at −80 ◦ C,
subjected to three freeze-and-thaw cycles, processed and placed on the LC system auto-sampler,
were determined to assess the stability of the GMC1 under anticipated storage and handling conditions,
as well as processing and sample analysis conditions. The results of the stability study (expressed as
the average percent of initial GMC1 concentration remaining) are summarized in Table 4.
Table 4. Stability of GMC1 in samples for LC-MS/MS analysis (n = 3; mean (± SD)).
Biological
Matrix

Time

Mean Recovery ± SD (%)

Plasma

2h
4h
6h
14 d

97.4 ± 8.9
88.9 ± 2.6
80.1 ± 5.7
101.2 ± 0.8

Urine

2h
4h
6h
14 d

94.2 ± 4.7
93.9 ± 0.7
93.7 ± 1.2
97.0 ± 2.6

Short-term/
Long-term Stability

Time(h)
Processed sample
Or Auto-sampler stability

Freeze-thaw Cycle
Stability

Mean Recovery ± SD (%)
No IS

With IS

Plasma

2
4
6

94.7 ± 7.9
99.7 ± 4.6
98.4 ± 6.2

89.9 ± 4.7
97.5 ± 1.5
96.2 ± 5.6

Urine

2
4
6

96.1 ± 2.4
89.7 ± 8.8
95.2 ± 2.1

96.4 ± 2.8
98.5 ± 1.1
97.1 ± 4.8

Quality Control
Sample

Mean Recovery ± SD (%)

Plasma

LQC
MQC
HQC

106.0 ± 5.9
98.5 ± 3.7
94.1 ± 2.9

Urine

LQC
MQC
HQC

113.0 ± 8.9
101.0 ± 3.9
86.6 ± 7.5

The bench-top stability data suggest that GMC1 is stable in rat plasma placed on the bench-top at
room temperature for up to 4 h. The decreased percentage recovery at 6 h suggest that plasma samples
should be immediately processed once thawed at room temperature. On the other hand, GMC1 is
stable in rat urine at the same conditions for up to 6 h. The long-term storage stability was assessed in
by analyzing QC samples stored at −80 ◦ C for 14 days. Recoveries of 101.2 ± 0.8% and 97.0 ± 2.6%,
respectively, in rat plasma and urine suggest that the analyte is stable when samples are frozen (at least
for 14 days) before analysis. Mean recoveries from freeze-and-thaw cycled samples were greater than
94.1 ± 2.9% and 86.6 ± 7.5% for plasma and urine, respectively. This suggests that the analyte is stable
in samples refrozen after being allowed to thaw at room temperature.
The effect of the IS on GMC1 recovery and stability was assessed by extracting the QC samples for
an auto-sampler stability test with either pure methanol or methanol containing IS. The processed
plasma and urine samples were stored on the LC system autosampler (temperature 10 ◦ C) for up to
6 h before analysis. The average percentage recoveries, summarized in Table 4, suggest that GMC1 is
stable in the extracted samples stored on the LC system for at least 6 h prior to analysis, and its stability
is not affected by the IS.
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2.3. Pharmacokinetic Study
The validated LC-MS/MS method was deployed to quantify GMC1 in rat plasma and urine
samples from pharmacokinetic study of GMC1 in SD rats. Adult male SD rats were dosed a single
2 mg/kg i.v. bolus of GMC1. Plasma and urine samples collected from the study were analyzed using
this assay method for GMC1 concentrations.
The plasma concentration—time profile, shown in Figure 3, illustrates that GMC1 is rapidly
distributed after administration. Elimination appears to be slow after the rapid distribution phase.
Table 5 shows the mean pharmacokinetic parameters describing the disposition of GMC1 in rats.
In summary, following the administration of GMC1, an average maximum plasma concentration
(Cmax ) of 2.5 ± 0.6 mg/L was reached, rapidly declining within the first two h, and steadily tailing off
in the terminal elimination phase. GMC1 has an elimination half-life of 14.8 ± 4.2 h, mean residence
time of 10.7 ± 4.4 h and total plasma clearance of 1.7 ± 0.2 L/h/kg. Its volume of distribution in rats is
greater than rat total body water (Vd : 36.9 ± 9.7 L/kg). GMC1 is eliminated by mechanisms displaying
first-order kinetics in rats. It appears to be extensively metabolized or eliminated by the biliary route.
Only 0.01% of the total dose administered was excreted unchanged in urine 24 h after administration.
Table 5. Pharmacokinetic parameters (mean ± SD) of GMC1 in SD rats following a single 2 mg/kg IV
bolus dose of GMC1.
Pharmacokinetic
Parameter (Unit)

Mean ± SD
(n = 4)

C0 (mg/L)
AUC0−∞ (h*mg/L)
T1/2 (h)
VD (L/kg)
Vss (L/kg)
Cl (L/h/kg)
MRT (h)

2.5 ± 0.63
1.2 ± 0.12
14.8 ± 4.2
36.9 ± 9.7
18.3 ± 6.7
1.7 ± 0.2
10.7 ± 4.4

C0 = concentration at time zero; AUC0−∞ = area under curve from time zero to infinity; T1/2 = elimination half-life;
VD = apparent volume of distribution; Vss = volume of distribution at steady state; Cl = total clearance; MRT = mean
residence time.

Figure 3. Cont.
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Figure 3. Pharmacokinetic study of GMC1 in adult male Sprague-Dawley (SD) rats (n = 4; average body
weight = 0.33 ± 0.005 kg). (A) Plasma concentration—time profiles of GMC1 following a 2 mg/kg i.v.
bolus dose, (B) Cumulative percentage of the administered dose of GMC1 excreted unchanged in urine.

3. Materials and Methods
3.1. Materials
GMC1, of purity ≥ 98%, was custom synthesized by ChemBridge™ (San Diego, CA, USA).
Albendazole, formic acid, LC-MS grade methanol and water were purchased from Sigma Aldrich (St.
Louis, MO, USA). Heparin sodium (1000 units/mL) and pharmaceutical grade normal saline (0.9% v/v)
were purchased from Hospira Inc. (Lake Forest, IL, USA). Fresh rat plasma and urine were obtained
from male SD rats purchased from Envigo RMS Inc. (Indianapolis, IN, USA), and stored at −80 ◦ C
until use.
3.2. Instruments and Conditions
Chromatographic separation was achieved with a Waters XTerra® MS C18 column (2.1 × 50 mm,
3.5 µm, 125 Å, Milford, MA, USA) on a Shimadzu Nexera X2 UHPLC System (Columbia, MD, USA).
A binary solvent system was used as mobile phase; Solvent A was 0.1% (v/v) formic acid in LC-MS
grade water and Solvent B was 0.1% (v/v) formic acid in LC-MS grade methanol. Sample analysis was
performed using a two-phase gradient elution set to 10% B from initial to 0.40 min, 35% B at 0.45 min,
95% B from 2.5 to 3.5 min, and 10% B from 3.55 to 4.5 min at a flow rate of 0.5 mL/min (Table 6). A 10 µL
of protein precipitated sample was injected in each run.
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Table 6. Gradient elution profile for the chromatographic separation of GMC1 and IS from matrices.
Mobile Phase A—0.1% (v/v) formic acid in water and mobile phase B—0.1% (v/v) formic acid in methanol.
Time (min)

Flow Rate (mL/min)

Mobile Phase A (%)

Mobile Phase B (%)

Initial
0.40
0.45
2.50
3.50
3.55
4.50

0.5
0.5
0.5
0.5
0.5
0.5
0.5

90
90
65
5
5
90
90

10
10
35
95
95
10
10

A 4000 QTRAP® mass spectrometer (MS) from AB Sciex (Foster City, CA, USA) which is a hybrid
triple quadrupole linear ion trap (LIT) MS equipped with a Turbo V™ ion source, was used for mass
spectral analysis. A GENIUS ABN2ZA Tri Gas Generator from Peak Scientific (Inchinnan, Scotland,
UK) was used to generate pure nitrogen used as curtain gas, source and exhaust gases. The transition
ions from a precursor ion ([M+H]+ ) to selected product ion for GMC1 m/z 340.995 → m/z 191.000) and
internal standard m/z 266.013 → m/z 234.000) were detected in positive ionization mode by multiple
reaction monitoring (MRM). Albendazole, a benzimidazole like GMC1, was selected as an internal
standard (IS). The IonSpray voltage was set to 1100 V; the curtain gas was set to 25 psi and the collision
CAD gas was set to high. The source heater was maintained at 700 ◦ C with both the nebulizer gas and
heater gas set to 50 and 30 psi, respectively. The collision energy was set at 27 eV for GMC1 and IS,
respectively. Compound dependent parameters such as entrance potential (EP) and dwell time were
optimized: EP of 10.00 V and dwell time of 50 ms for GMC1 and IS was employed. System control,
acquisition data collection and processing were performed on the Analyst® software v1.6.2 (Sciex,
Foster City, CA, USA). The compound specific parameters are summarized in Table 7. The chemical
structures of GMC1 and IS, and their MS fragmentation patterns are shown in Figures 1 and 4.
Table 7. Compound specific parameters for MS/MS acquisition of GMC1 and IS (albendazole).
Parent

Transition
(m/z)

Dwell Time
(msec)

DP
(Volts)

EP
(Volts)

CE
(Volts)

CXP
(Volts)

GMC1
Albendazole (IS)

340.995 → 191.000
266.013 → 234.000

50
50

81.0
86.0

10.0
10.0

27.0
27.0

10.0
14.0

3.3. Preparation of Standard and Quality Control Samples
Working stock solutions of GMC1 and IS, prepared in LC-MS grade methanol at 1 mg/mL and
0.5 mg/mL, respectively, were stored at −20 ◦ C until use. Working standard solutions containing ten
times the final desired concentrations of calibrators and quality control (QC) samples were prepared
in 50% methanol in water. Blank, zero and non-zero calibrators were prepared in blank rat plasma
and urine at GMC1 concentrations ranging from 1–1000 ng/mL. Quality control (QC) samples were
also prepared in blank rat plasma and urine at LLOQ (1 ng/mL), low (LQC: 2.5 ng/mL), medium
(MQC: 400 ng/mL) and high (HQC: 800 ng/mL) concentrations of GMC1. All plasma and urine samples
were processed for LC-MS/MS analysis by simple protein precipitation using methanol. Briefly, 5 µL
of blank or standard working solutions, respectively, were spiked onto 45 µL of rat plasma or urine.
Then 200 µL of precipitant (methanol containing 25 ng/mL of IS) was added and vortexed for 30 s.
The mixture was centrifuged for 10 min at 14,000 rpm and 4 ◦ C. The recovered supernatant was then
transferred to an auto-sampler vial for injection on the LC-MS/MS system.
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Figure 4. Product ion spectra. (A) GMC1 precursor ion (m/z 341.2) and product ions (m/z 190.8, 151.0
and 134.2); (B) Albendazole (IS) precursor ion (m/z 266.0) and product ions (m/z 234.0, 191.0 and 159.2).
Their exact masses are 340.099 and 265.088, respectively. [M+H]+ ions were selected as precursor ions.

3.4. Sample Preparation
Plasma and urine samples obtained from pharmacokinetic study subjects were stored at –80 ◦ C
until analysis. The plasma samples were prepared for LC-MS/MS analysis by a simple protein
precipitation method, as described in the previous section. Briefly, 50 µL of plasma sample was
extracted with 200 µL of precipitant (methanol containing 25 ng/mL of IS) followed by vortex mixing for
30 s. The mixture was then centrifuged for 10 min at 14,000 rpm and 4 ◦ C. The recovered supernatant
was then transferred to an auto-sampler vial for injection on the LC-MS/MS system. The rat urine
samples were prepared in a similar manner.
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3.5. Method Validation
A full validation of the LC-MS/MS method was performed according to the “US FDA, Center
for Drug Evaluation and Research: Guidance for Industry—Bioanalytical Method Validation” [17].
The validated parameters were sensitivity and linearity, specificity and selectivity, accuracy and
precision, dilution integrity, matrix effect, extraction recovery and analyte stability.
3.5.1. Specificity and Selectivity
Blank rat plasma and urine samples from six different sources were analyzed to exclude any
endogenous co-eluting interference or peaks close to the expected retention times of analytes and IS.
The assay selectivity and specificity were also assessed by comparing the instrument response for the
IS in blank samples to the average instrument response for IS in standards and QCs.
3.5.2. Sensitivity and Linearity
The sensitivity of the assay was determined by analyzing six replicates of lower limit of
quantification (LLOQ) QC in plasma and urine. Precision and accuracy ≥ 20% were considered
acceptable to establish sensitivity. The LLOQ was based on a signal-to-noise (S/N) ratio greater than
5:1 while the limit of detection (LOD) was defined based on an S/N of 3:1.
Linearity was assessed by plotting calibration curves of GMC1 in rat plasma and urine, respectively.
The calibration curves were constructed by plotting the peak area ratio (PAR) of GMC1 to IS against
nominal concentrations of GMC1. Parameters such as slope, intercept and correlation coefficient of
linear regression equation were estimated using least square regression analysis using a 1/x2 weighting.
3.5.3. Precision, Accuracy and Dilution Integrity
Six replicates of LLOQ, LQC, MQC and HQC samples were analyzed using a calibration curve
constructed on the same day to determine the intra-day accuracy and precision. The inter-day accuracy
and precision was determined by analyzing six replicates of LLOQ QC, LQC, MQC and HQC samples
using 3 different calibration curves constructed on three different days. The assay accuracy was
established by the percentage relative error (% RE) from the nominal GMC1 concentrations, while the
percentage coefficient of variation (% CV) was considered as the assay precision. The accuracy and
precision in rat plasma and urine were determined in a similar manner.
The dilution integrity was established by determining the accuracy and precision of the
measurement of rat plasma and urine samples with a GMC1 concentration 2.5X of the highest
standard and diluted with up to 50 times to fall within the linear range of the assay. Rat plasma and
urine samples containing 2500 ng/mL of GMC1 were prepared and diluted 5, 10, 20, and 50 times
with blank rat plasma or 5, 12.5, 25 and 50 times with blank rat urine, respectively. This experiment
was conducted in sextuplets. Following LC-MS/MS analysis, the concentrations of six replicates were
corrected with the dilution factor and the percent accuracy and precision were then determined.
3.5.4. Extraction Recovery
The extraction recovery was determined by analyzing triplicates of QC samples, rat plasma
and urine spiked with the respective concentrations of GMC1, before or after protein precipitation.
The percentage recovery of GMC1 was calculated using Equation (1):
% Recovery =

Responsepre−extraction spike sample
Responsepost−extraction spike sample

× 100%

(1)

where Responsepre-extraction spike sample is the average peak area count for GMC1 in plasma or urine
sample spike with the analyte pre-protein precipitation, and Responsepost-extraction spike sample is the
average peak area count for samples spiked with GMC1 after protein extraction.
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3.5.5. Matrix Effect
The matrix effect was determined to assess the effect of components of biological matrices on the
quantification of GMC1 in such biological matrices. A set of rat plasma and urine QC samples and QC
samples in a neat solution (35% methanol) were analyzed to determine the matrix effect. Equation (2)
was used to calculate the matrix factor:


 Responsepost−extraction spike sample − Responseneat sample 
Matrix factor (%) = 
(2)
 × 100
Response neat sample
where Responsepost-extraction spike sample is the mean peak area for a sample spiked with GMC1 post
protein precipitation, and Responseneat sample is the mean peak area for QC samples of same GMC1
concentration in matrix-free solution (35% methanol).
Interference of analyte signal by co-eluting PEG, used as an excipient in dosing solutions for
pharmacokinetic studies, is well documented [19,20]. Signal interference by PEG 300 used in this study
was evaluated by determining the precision and accuracy of six replicates of QC samples prepared
in rat plasma spiked with 0.1% PEG 300 and 1% PEG 300, respectively. The PEG QC samples were
compared to plasma QC samples devoid of PEG 300.
3.5.6. Analyte Stability
The stability of GMC1 in samples under anticipated storage and handling conditions, as well as
sample preparation and LC-MS/MS analysis procedures was assessed by determining the percentage
recovery of the analyte from samples subjected to short-term storage on the bench-top, freeze-and-thaw
cycles, and processed and stored on the LC system auto-sampler prior to analysis. All the stability test
experiments were conducted in triplicates.
Three sets of plasma and urine QC samples were left on the bench-top for 2, 4, and 6 h, respectively;
each set was analyzed and compared to fresh samples of the same analyte concentration to establish
the bench-top storage (short-term) stability of GMC1 in rat plasma and urine. The long-term stability
of samples stored in frozen condition (−80 ◦ C) before analysis was assessed by measuring the mean
percentage recovery of GMC1 from rat plasma and urine samples stored for 14 days. The instrument
response from the frozen samples was compared to the mean response from freshly prepared samples.
The stability of GMC1 in rat plasma and urine samples after freeze–thaw cycle was evaluated
by analyzing QC samples exposed to three cycles of freeze (at −80 ◦ C) and thaw (room temperature).
The mean percentage recoveries from the samples were measured against fresh QC samples of the
same GMC1 concentration. Additionally, GMC1 stability in processed (protein precipitated) samples
stored on the autosampler before LC-MS/MS analysis was assessed by analyzing plasma and urine
QC samples extracted with methanol and placed in the auto-sampler for 2 to 6 h prior to analysis.
A set of the samples was precipitated with methanol containing IS, while the other set with plain
methanol (without IS). Both sample sets were compared to fresh samples of similar GMC1 concentration.
The temperature of the auto-sampler was set to 10 ◦ C.
3.6. Pharmacokinetic Study
Adult male SD rats (body weight 300 to 350 g) were purchased from Envigo RMS, Inc, (Indianapolis,
IN, USA) and kept in an environmentally controlled room (fed ad libitum) for at least one week before
experiments. The protocol for the animal experiment was reviewed and approved by the Institutional
Animal Care and Use Committee at Texas Southern University, and all animal experiments were
conducted according to the National Institute of Health “Guide for the Care and Use of Laboratory
Animals, 8th Edition” [21].
Jugular veins of the rats (n = 4) were cannulated under anesthesia one day prior to the study.
A co-solvent formulation containing 10 mg/mL of GMC1 in 50% v/v of Labrasol® and PEG 300,
respectively, was prepared and diluted 10X with normal saline prior to administration. Each rat was
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administered a single 2 mg/kg intravenous (i.v.) bolus dose of the diluted GMC1 solution. About 250 µL
serial blood was obtained from each rat prior to dosing and at 5, 15 and 30 min, 1, 2, 4, 6, 8, 12, 24 and 48 h
after administration into heparinized blood sample collecting tubes. The blood was centrifuged to obtain
plasma which was frozen at −80 ◦ C until LC-MS/MS analysis. Urine from each rat was also collected for
up to 24 h after dosing and also stored at the same condition until analysis. GMC1 concentration in the
plasma and urine samples was determined within 48 h using our LC-MS/MS assay method.
3.7. Pharmacokinetic Analysis
Pharmacokinetic parameters for GMC1 were estimated using Phoenix WinNonlin v7.0
(Certara USA Inc., Princeton, NJ, USA). Non-compartmental analysis was performed to estimate the
terminal elimination half-life (t1/2 ), total clearance (CL), area under the plasma concentration time curve
(AUC0–∞ ), plasma concentration at time zero (C0 ), apparent volume of distribution (VD), volume of
distribution at steady state (Vss), and mean residence time (MRT). The AUC0−∞ was calculated by a
linear log trapezoidal (linear up log down) method. Uniform weighting scheme as well as 1/Y, 1/Y2 ,
and 1/(Yhat)2 were compared for the most suitable weighting for the non-compartmental analysis.
The optimal weighting was selected based on the correlation coefficient and observed vs. predicted fit
of the plasma concentration vs. time plot. Based on these criteria, the uniform weighting scheme was
most suited for the pharmacokinetic analysis on the individual profiles.
4. Conclusions
A simple, sensitive, and reproducible LC-MS/MS method was developed and fully validated for
quantification of levels of the novel drug candidate, GMC1, in plasma and urine samples. This method
was confirmed to be accurate and precise for the quantification of GMC1 in samples within the linear
range of assay, from 1–1000 ng/mL of GMC1. The analyte stability in biological samples was not
impacted by anticipated sample storage, handling, preparation, and LC-MS/MS analysis conditions,
or the presence or absence of an internal standard and was also easily extractable from the biological
matrices by simple protein precipitation. The pharmacokinetic data from this study revealed that
GMC1 has a bi-phasic disposition in adult male SD rats. It is distributed extensively and is eliminated
primarily by first order kinetics; it has a long plasma elimination half-life. This LC-MS/MS assay
method will be very essential in subsequent studies of GMC1.
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